Biofrontera Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Operating expenses | $53.1M | $54.5M | $56.7M | $47.3M | $49.3M |
| Cash from operations | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M |
| Capital expenditure | $2,000 | $10,000 | $5,000 | $38,000 | — |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — |
| Impairments | $0 | $0 | — | — | — |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
Shares outstanding 12.8M · Free float 24.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.